There is change in your pharmacies today, especially if you are diabetic or if you have a treatment for obesity. From this September 1, 2025, in fact, you must present specific proof to continue to be reimbursed from certain antidiabetics such as Ozempic®.
An announced hardening, which is explained
Indeed, these treatments belong to the family of the analogues of GLP-1, a hormone which regulates blood sugar. Indispensable for many diabetic patients, they cost around € 80 per box. Without them, the metabolic imbalance sets up: increase in blood sugar, weight gain, increase in cardiovascular risks …
But over the years, these drugs have aroused a craze exceeding the medical framework. Because behind their virtue on the metabolism of diabetic people, they allow you to lose weight, quickly and without diet. Their appetite suppressant effect and their action on satiety have attracted many people in search of weight loss, so much so that many personalities praise it today. Since June, it is also possible for French general practitioners to prescribe this drug which “melts”. Problem: this “slimming” use for aesthetic purposes constitutes a diversion of use and therefore does not open up any right to reimbursement.
Despite everything, health insurance (CNAM) and the ANSM have noted a multiplication of prescriptions outside the framework, diverting part of the stocks to the detriment of diabetic patients.
A new control device
To ensure that these drugs remain available for patients who really need them, a compulsory form was therefore established in early 2025. And a change in three stages was put in place:
- Since June 1, 2025: reimbursement in pharmacy requires the presentation of this proof, in addition to the prescription;
- Until August 31, 2025: Tolerance still allowed a posteriori refund, after advance the costs;
- From September 1, 2025 (today): end of this flexibility. Without proof, no refund will be granted.
This proof, fulfilled by the doctor via Amelipro, attests that the prescription respects the AMM (marketing authorization). The pharmacist must verify this before invoicing treatment to health insurance.
In the event of a prescription outside the AMM, the doctor must indicate the mention “non -refundable” (NR) on the prescription. The patient can then obtain his treatment, but at his own expense.
What are the drugs concerned?
The device targets four GLP-1 analogues used in the treatment of type 2 diabetes:
- Ozempic® (semaglutide);
- Trulicity® (Dulaglutide);
- Victoza® (Liraglutide);
- Byetta® (Exénatide).
On the other hand, the GLP-1 analogues specifically authorized in obesity, Wegovy® (Sémaglutide), Mounjaro® (Tirzepatide) and Saxenda® (Liraglutide), are not affected by this device. The latter are never reimbursed and remain accessible only on prescription, at a price around € 300 per box. There is therefore no change for them.